345 related articles for article (PubMed ID: 18349408)
21. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
Leukemia; 2007 Mar; 21(3):524-8. PubMed ID: 17268531
[TBL] [Abstract][Full Text] [Related]
22. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma.
Eve HE; Furtado MV; Hamon MD; Rule SA
J Clin Oncol; 2009 Nov; 27(32):e189-90; author reply e191. PubMed ID: 19805667
[No Abstract] [Full Text] [Related]
23. Primary gastrointestinal tract mantle cell lymphoma as multiple lymphomatous polyposis.
Ruskoné-Fourmestraux A; Audouin J
Best Pract Res Clin Gastroenterol; 2010 Feb; 24(1):35-42. PubMed ID: 20206107
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
[TBL] [Abstract][Full Text] [Related]
25. Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Dasanu CA; Reale MA; Bauer F
Leuk Res; 2010 Jul; 34(7):e178-80. PubMed ID: 20079532
[No Abstract] [Full Text] [Related]
26. R-CHOP therapy for MALT lymphoma of the rectum.
Chihara D; Kagami Y; Oki Y; Kato H; Onoda H; Ine S; Taji H; Yamamoto K; Morishima Y
Eur J Haematol; 2010 Jan; 84(1):84-6. PubMed ID: 19737307
[No Abstract] [Full Text] [Related]
27. Canonical nuclear factor κB pathway links tumorigenesis of synchronous mantle-cell lymphoma, clear-cell renal-cell carcinoma, and GI stromal tumor.
Guo R; Chang L; Liu Z; Li AX; Huang Q; Ann DK; Wang HC; Lin CW; Wu X; Yuan YC; Yen Y
J Clin Oncol; 2011 Apr; 29(10):e257-61. PubMed ID: 21220613
[No Abstract] [Full Text] [Related]
28. Successful treatment of focal segmental glomerulosclerosis in association with mantle cell lymphoma.
Wong CF; Mohteshamzadeh M; Arsalanizadeh B; Dutt T; Shawki H; Khine MM; Rustom R
Ren Fail; 2007; 29(3):363-6. PubMed ID: 17497453
[No Abstract] [Full Text] [Related]
29. Diffuse gastrointestinal involvement of mantle cell lymphoma.
Meral M; Demirpençe M; Gönen C; Akarsu M; Kayahan H; Demirkan F; Kargi A; Akpinar H
Turk J Gastroenterol; 2008 Jun; 19(2):117-20. PubMed ID: 19110668
[TBL] [Abstract][Full Text] [Related]
30. Multiple lymphomatous polyposis form is common but not specific for mantle cell lymphoma in the gastrointestinal tract.
Okazaki K
J Gastroenterol; 2004 Oct; 39(10):1023-4. PubMed ID: 15549463
[No Abstract] [Full Text] [Related]
31. What to do when you suspect gastrointestinal lymphoma: a pathologist's perspective.
Gurbuxani S; Anastasi J
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):417-21. PubMed ID: 17336592
[TBL] [Abstract][Full Text] [Related]
32. Unusual sites of involvement in non-Hodgkin's lymphoma: Case 3. Intussusception as a rare complication of mantle-cell lymphoma.
Sucker C; Klima KM; Doelken G; Heidecke CD; Lorenz G; Stockschlaeder M
J Clin Oncol; 2002 Nov; 20(21):4397-8. PubMed ID: 12409341
[No Abstract] [Full Text] [Related]
33. Angioimmunoblastic lymphadenopathy: an etiology for gastrointestinal lymphomatous polyposis.
Goenka MK; Vaiphei K; Nagi B; Sriram PV; Joshi K; Kochhar R
Am J Gastroenterol; 1996 Jun; 91(6):1236-8. PubMed ID: 8651178
[TBL] [Abstract][Full Text] [Related]
34. Increasing chemotherapy intensity in aggressive lymphomas: a renewal?
Coiffier B
J Clin Oncol; 2003 Jul; 21(13):2457-9. PubMed ID: 12829662
[No Abstract] [Full Text] [Related]
35. Magnifying endoscopic observation of mantle cell lymphoma in the stomach using the narrow-band imaging system.
Nonaka K; Ishikawa K; Arai S; Shimizu M; Sakurai T; Nishimura M; Nakao M; Sasaki Y; Kita H
Endoscopy; 2010; 42 Suppl 2():E94-5. PubMed ID: 20195984
[No Abstract] [Full Text] [Related]
36. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
[TBL] [Abstract][Full Text] [Related]
37. [Primary subcutaneous mantle cell lymphoma treated successfully with THP-COP therapy].
Hisatake J; Kawakami K; Nakamaki T; Hino K; Tomoyasu S
Rinsho Ketsueki; 2002 May; 43(5):384-8. PubMed ID: 12096492
[TBL] [Abstract][Full Text] [Related]
38. [Two cases of malignant lymphoma with high fever and C-reactive protein (CRP) elevation after treatment with granulocyte colony-stimulating factor (G-CSF)].
Kanbayashi Y; Mukoyama N; Nishida K; Shimizu D; Matsumoto Y; Nomura K; Horiike S; Taniwaki M
Gan To Kagaku Ryoho; 2006 Jan; 33(1):73-7. PubMed ID: 16410701
[TBL] [Abstract][Full Text] [Related]
39. R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma.
Lim SH; Esler WV; Periman PO; Beggs D; Zhang Y; Townsend M
Br J Haematol; 2008 Jul; 142(3):482-4. PubMed ID: 18510683
[No Abstract] [Full Text] [Related]
40. [The choice of second-line chemotherapy for malignant lymphoma].
Ikeda T; Hotta T
Gan To Kagaku Ryoho; 2005 Jan; 32(1):6-10. PubMed ID: 15675573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
